Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer
Although there are molecularly distinct subtypes of prostate cancer, no molecular classification system is used clinically. The ribonucleotide reductase small subunit M2 (RRM2) gene plays an oncogenic role in many cancers. Our previous study elucidated comprehensive molecular mechanisms of RRM2 in p...
Main Authors: | Ying Z. Mazzu, Joshua Armenia, Subhiksha Nandakumar, Goutam Chakraborty, Yuki Yoshikawa, Lina E. Jehane, Gwo‐Shu Mary Lee, Mohammad Atiq, Nabeela Khan, Nikolaus Schultz, Philip W. Kantoff |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-08-01
|
Series: | Molecular Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1002/1878-0261.12706 |
Similar Items
-
Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2)
by: Guanggai Xia, et al.
Published: (2017-08-01) -
Regulatory Role of Ribonucleotide Reductase Subunit M2 in Hepatocyte Growth and Pathogenesis of Hepatitis C Virus
by: Bouchra Kitab, et al.
Published: (2023-01-01) -
The Prediction Analysis of Microarray 50 (PAM50) Gene Expression Classifier Utilized in Indeterminate-Risk Breast Cancer Patients in Hungary: A Consecutive 5-Year Experience
by: Magdolna Dank, et al.
Published: (2023-08-01) -
A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumors
by: Yaqun Li, et al.
Published: (2022-11-01) -
Ribonucleotide reductase M2 (RRM2): Regulation, function and targeting strategy in human cancer
by: Zanwen Zuo, et al.
Published: (2024-01-01)